Selected research
Market Structure
Global Human VEGF Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Human VEGF Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Human VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Human VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Human VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Human VEGF Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Human VEGF Antibody include Abcam, Abnova, Absolute Antibody, Agrisera, BioLegend, Bio-Rad, Bon Opus Biosciences, Boster and Creative Biomart, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Human VEGF Antibody market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Human VEGF Antibody and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Human VEGF Antibody sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human VEGF Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.
Human VEGF Antibody Segment by Company
Abcam
Abnova
Absolute Antibody
Agrisera
BioLegend
Bio-Rad
Bon Opus Biosciences
Boster
Creative Biomart
Enzo Life Sciences
ImmunoStar
LifeSpan Biosciences
MilliporeSigma
Novus Biologicals
OriGene
ProMab
R&D Systems
Rockland Immunochemicals
Santa Cruz Biotechnology
Sino Biological
US Biological
Thermo Fisher
Human VEGF Antibody Segment by Type
Rabbit
Mouse
Goat
Others
Human VEGF Antibody Segment by Application
Laboratory
Hospital
Others
Human VEGF Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human VEGF Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human VEGF Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human VEGF Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Human VEGF Antibody market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Human VEGF Antibody manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Human VEGF Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Human VEGF Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
List of Tables
Table 1. Human VEGF Antibody Industry Trends
Table 2. Human VEGF Antibody Industry Drivers
Table 3. Human VEGF Antibody Industry Opportunities and Challenges
Table 4. Human VEGF Antibody Industry Restraints
Table 5. Global Human VEGF Antibody Revenue by Manufacturers (US$ Million) & (2021-2026)
Table 6. Global Human VEGF Antibody Revenue Market Share by Manufacturers (2021-2026)
Table 7. Global Human VEGF Antibody Sales by Manufacturers (Kg) & (2021-2026)
Table 8. Global Human VEGF Antibody Sales Market Share by Manufacturers
Table 9. Global Human VEGF Antibody Average Sales Price (US$/g) of Manufacturers (2021-2026)
Table 10. Global Human VEGF Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
Table 11. Global Human VEGF Antibody Key Manufacturers Manufacturing Sites & Headquarters
Table 12. Global Human VEGF Antibody Manufacturers, Product Type & Application
Table 13. Global Human VEGF Antibody Manufacturers Establishment Date
Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15. Global Human VEGF Antibody by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025)
Table 16. Major Manufacturers of Rabbit
Table 17. Major Manufacturers of Mouse
Table 18. Major Manufacturers of Goat
Table 19. Major Manufacturers of Others
Table 20. Global Human VEGF Antibody Sales by Type 2021 VS 2025 VS 2032 (Kg)
Table 21. Global Human VEGF Antibody Sales by Type (2021-2026) & (Kg)
Table 22. Global Human VEGF Antibody Sales by Type (2027-2032) & (Kg)
Table 23. Global Human VEGF Antibody Sales Market Share by Type (2021-2026)
Table 24. Global Human VEGF Antibody Sales Market Share by Type (2027-2032)
Table 25. Global Human VEGF Antibody Revenue by Type 2021 VS 2025 VS 2032 (Kg)
Table 26. Global Human VEGF Antibody Revenue by Type (2021-2026) & (Kg)
Table 27. Global Human VEGF Antibody Revenue by Type (2027-2032) & (Kg)
Table 28. Global Human VEGF Antibody Revenue Market Share by Type (2021-2026)
Table 29. Global Human VEGF Antibody Revenue Market Share by Type (2027-2032)
Table 30. Major Manufacturers of Laboratory
Table 31. Major Manufacturers of Hospital
Table 32. Major Manufacturers of Others
Table 33. Global Human VEGF Antibody Sales by Application 2021 VS 2025 VS 2032 (Kg)
Table 34. Global Human VEGF Antibody Sales by Application (2021-2026) & (Kg)
Table 35. Global Human VEGF Antibody Sales by Application (2027-2032) & (Kg)
Table 36. Global Human VEGF Antibody Sales Market Share by Application (2021-2026)
Table 37. Global Human VEGF Antibody Sales Market Share by Application (2027-2032)
Table 38. Global Human VEGF Antibody Revenue by Application 2021 VS 2025 VS 2032 (Kg)
Table 39. Global Human VEGF Antibody Revenue by Application (2021-2026) & (Kg)
Table 40. Global Human VEGF Antibody Revenue by Application (2027-2032) & (Kg)
Table 41. Global Human VEGF Antibody Revenue Market Share by Application (2021-2026)
Table 42. Global Human VEGF Antibody Revenue Market Share by Application (2027-2032)
Table 43. Global Human VEGF Antibody Sales by Region: 2021 VS 2025 VS 2032 (Kg)
Table 44. Global Human VEGF Antibody Sales by Region (2021-2026) & (Kg)
Table 45. Global Human VEGF Antibody Sales Market Share by Region (2021-2026)
Table 46. Global Human VEGF Antibody Sales Forecasted by Region (2027-2032) & (Kg)
Table 47. Global Human VEGF Antibody Sales Forecasted Market Share by Region (2027-2032)
Table 48. North America Human VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg)
Table 49. North America Human VEGF Antibody Sales by Country (2021-2026) & (Kg)
Table 50. North America Human VEGF Antibody Sales by Country (2027-2032) & (Kg)
Table 51. Europe Human VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg)
Table 52. Europe Human VEGF Antibody Sales by Country (2021-2026) & (Kg)
Table 53. Europe Human VEGF Antibody Sales by Country (2027-2032) & (Kg)
Table 54. Asia Pacific Human VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg)
Table 55. Asia Pacific Human VEGF Antibody Sales by Country (2021-2026) & (Kg)
Table 56. Asia Pacific Human VEGF Antibody Sales by Country (2027-2032) & (Kg)
Table 57. South America, Middle East and Africa Human VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (Kg)
Table 58. South America, Middle East and Africa Human VEGF Antibody Sales by Country (2021-2026) & (Kg)
Table 59. South America, Middle East and Africa Human VEGF Antibody Sales by Country (2027-2032) & (Kg)
Table 60. Global Human VEGF Antibody Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Table 61. Global Human VEGF Antibody Revenue by Region (2021-2026) & (US$ Million)
Table 62. Global Human VEGF Antibody Revenue by Region (2027-2032) & (US$ Million)
Table 63. Global Human VEGF Antibody Revenue Market Share by Region (2021-2026)
Table 64. Global Human VEGF Antibody Revenue Market Share by Region (2027-2032)
Table 65. Abcam Company Information
Table 66. Abcam Business Overview
Table 67. Abcam Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 68. Abcam Human VEGF Antibody Product Portfolio
Table 69. Abcam Recent Development
Table 70. Abnova Company Information
Table 71. Abnova Business Overview
Table 72. Abnova Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 73. Abnova Human VEGF Antibody Product Portfolio
Table 74. Abnova Recent Development
Table 75. Absolute Antibody Company Information
Table 76. Absolute Antibody Business Overview
Table 77. Absolute Antibody Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 78. Absolute Antibody Human VEGF Antibody Product Portfolio
Table 79. Absolute Antibody Recent Development
Table 80. Agrisera Company Information
Table 81. Agrisera Business Overview
Table 82. Agrisera Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 83. Agrisera Human VEGF Antibody Product Portfolio
Table 84. Agrisera Recent Development
Table 85. BioLegend Company Information
Table 86. BioLegend Business Overview
Table 87. BioLegend Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 88. BioLegend Human VEGF Antibody Product Portfolio
Table 89. BioLegend Recent Development
Table 90. Bio-Rad Company Information
Table 91. Bio-Rad Business Overview
Table 92. Bio-Rad Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 93. Bio-Rad Human VEGF Antibody Product Portfolio
Table 94. Bio-Rad Recent Development
Table 95. Bon Opus Biosciences Company Information
Table 96. Bon Opus Biosciences Business Overview
Table 97. Bon Opus Biosciences Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 98. Bon Opus Biosciences Human VEGF Antibody Product Portfolio
Table 99. Bon Opus Biosciences Recent Development
Table 100. Boster Company Information
Table 101. Boster Business Overview
Table 102. Boster Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 103. Boster Human VEGF Antibody Product Portfolio
Table 104. Boster Recent Development
Table 105. Creative Biomart Company Information
Table 106. Creative Biomart Business Overview
Table 107. Creative Biomart Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 108. Creative Biomart Human VEGF Antibody Product Portfolio
Table 109. Creative Biomart Recent Development
Table 110. Enzo Life Sciences Company Information
Table 111. Enzo Life Sciences Business Overview
Table 112. Enzo Life Sciences Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 113. Enzo Life Sciences Human VEGF Antibody Product Portfolio
Table 114. Enzo Life Sciences Recent Development
Table 115. ImmunoStar Company Information
Table 116. ImmunoStar Business Overview
Table 117. ImmunoStar Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 118. ImmunoStar Human VEGF Antibody Product Portfolio
Table 119. ImmunoStar Recent Development
Table 120. LifeSpan Biosciences Company Information
Table 121. LifeSpan Biosciences Business Overview
Table 122. LifeSpan Biosciences Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 123. LifeSpan Biosciences Human VEGF Antibody Product Portfolio
Table 124. LifeSpan Biosciences Recent Development
Table 125. MilliporeSigma Company Information
Table 126. MilliporeSigma Business Overview
Table 127. MilliporeSigma Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 128. MilliporeSigma Human VEGF Antibody Product Portfolio
Table 129. MilliporeSigma Recent Development
Table 130. Novus Biologicals Company Information
Table 131. Novus Biologicals Business Overview
Table 132. Novus Biologicals Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 133. Novus Biologicals Human VEGF Antibody Product Portfolio
Table 134. Novus Biologicals Recent Development
Table 135. OriGene Company Information
Table 136. OriGene Business Overview
Table 137. OriGene Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 138. OriGene Human VEGF Antibody Product Portfolio
Table 139. OriGene Recent Development
Table 140. ProMab Company Information
Table 141. ProMab Business Overview
Table 142. ProMab Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 143. ProMab Human VEGF Antibody Product Portfolio
Table 144. ProMab Recent Development
Table 145. R&D Systems Company Information
Table 146. R&D Systems Business Overview
Table 147. R&D Systems Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 148. R&D Systems Human VEGF Antibody Product Portfolio
Table 149. R&D Systems Recent Development
Table 150. Rockland Immunochemicals Company Information
Table 151. Rockland Immunochemicals Business Overview
Table 152. Rockland Immunochemicals Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 153. Rockland Immunochemicals Human VEGF Antibody Product Portfolio
Table 154. Rockland Immunochemicals Recent Development
Table 155. Santa Cruz Biotechnology Company Information
Table 156. Santa Cruz Biotechnology Business Overview
Table 157. Santa Cruz Biotechnology Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 158. Santa Cruz Biotechnology Human VEGF Antibody Product Portfolio
Table 159. Santa Cruz Biotechnology Recent Development
Table 160. Sino Biological Company Information
Table 161. Sino Biological Business Overview
Table 162. Sino Biological Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 163. Sino Biological Human VEGF Antibody Product Portfolio
Table 164. Sino Biological Recent Development
Table 165. US Biological Company Information
Table 166. US Biological Business Overview
Table 167. US Biological Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 168. US Biological Human VEGF Antibody Product Portfolio
Table 169. US Biological Recent Development
Table 170. Thermo Fisher Company Information
Table 171. Thermo Fisher Business Overview
Table 172. Thermo Fisher Human VEGF Antibody Sales (Kg), Price (US$/g), Revenue (US$ Million) and Gross Margin (2021-2026)
Table 173. Thermo Fisher Human VEGF Antibody Product Portfolio
Table 174. Thermo Fisher Recent Development
Table 175. Key Raw Materials
Table 176. Raw Materials Key Suppliers
Table 177. Human VEGF Antibody Distributors List
Table 178. Human VEGF Antibody Customers List
Table 179. Research Programs/Design for This Report
Table 180. Authors List of This Report
Table 181. Secondary Sources
Table 182. Primary Sources
List of Figures
Figure 1. Human VEGF Antibody Product Image
Figure 2. Global Human VEGF Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global Human VEGF Antibody Market Size (2021-2032) & (US$ Million)
Figure 4. Global Human VEGF Antibody Sales (2021-2032) & (Kg)
Figure 5. Global Human VEGF Antibody Average Price (US$/g) & (2021-2032)
Figure 6. Global Top 5 and 10 Human VEGF Antibody Players Market Share by Revenue in 2025
Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 8. Rabbit Image
Figure 9. Mouse Image
Figure 10. Goat Image
Figure 11. Others Image
Figure 12. Global Human VEGF Antibody Sales by Type (2021 VS 2025 VS 2032) & (Kg)
Figure 13. Global Human VEGF Antibody Sales Market Share 2021 VS 2025 VS 2032
Figure 14. Global Human VEGF Antibody Sales Market Share by Type (2021-2032)
Figure 15. Global Human VEGF Antibody Revenue by Type (2021 VS 2025 VS 2032) & (Kg)
Figure 16. Global Human VEGF Antibody Revenue Market Share 2021 VS 2025 VS 2032
Figure 17. Global Human VEGF Antibody Revenue Market Share by Type (2021-2032)
Figure 18. Laboratory Image
Figure 19. Hospital Image
Figure 20. Others Image
Figure 21. Global Human VEGF Antibody Sales by Application (2021 VS 2025 VS 2032) & (Kg)
Figure 22. Global Human VEGF Antibody Sales Market Share 2021 VS 2025 VS 2032
Figure 23. Global Human VEGF Antibody Sales Market Share by Application (2021-2032)
Figure 24. Global Human VEGF Antibody Revenue by Application (2021 VS 2025 VS 2032) & (Kg)
Figure 25. Global Human VEGF Antibody Revenue Market Share 2021 VS 2025 VS 2032
Figure 26. Global Human VEGF Antibody Revenue Market Share by Application (2021-2032)
Figure 27. North America Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 28. North America Human VEGF Antibody Sales Market Share by Country (2021-2032)
Figure 29. U.S. Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 30. Canada Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 31. Mexico Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 32. Europe Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 33. Europe Human VEGF Antibody Sales Market Share by Country (2021-2032)
Figure 34. Germany Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 35. France Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 36. U.K. Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 37. Italy Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 38. Netherlands Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 39. Asia Pacific Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 40. Asia Pacific Human VEGF Antibody Sales Market Share by Country (2021-2032)
Figure 41. China Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 42. Japan Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 43. South Korea Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 44. Southeast Asia Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 45. India Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 46. Australia Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 47. South America, Middle East and Africa Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 48. South America, Middle East and Africa Human VEGF Antibody Sales Market Share by Country (2021-2032)
Figure 49. Brazil Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 50. South Africa Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 51. Saudi Arabia Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 52. Turkey Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 53. Argentina Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 54. UAE Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 55. Egypt Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 56. Chile Human VEGF Antibody Sales and Growth Rate (2021-2032) & (Kg)
Figure 57. Global Human VEGF Antibody Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million)
Figure 58. Global Human VEGF Antibody Revenue Market Share by Region in Percentage: 2025 Versus 2032
Figure 59. North America Human VEGF Antibody Revenue (2021-2032) & (US$ Million)
Figure 60. North America Human VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 61. Europe Human VEGF Antibody Revenue (2021-2032) & (US$ Million)
Figure 62. Europe Human VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 63. Asia-Pacific Human VEGF Antibody Revenue (2021-2032) & (US$ Million)
Figure 64. Asia-Pacific Human VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 65. South America, Middle East and Africa Human VEGF Antibody Revenue (2021-2032) & (US$ Million)
Figure 66. South America, Middle East and Africa Human VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
Figure 67. Human VEGF Antibody Value Chain
Figure 68. Manufacturing Cost Structure
Figure 69. Human VEGF Antibody Production Mode & Process
Figure 70. Direct Comparison with Distribution Share
Figure 71. Distributors Profiles
Figure 72. Years Considered
Figure 73. Research Process
Figure 74. Key Executives Interviewed
Scope & coverage.
Types
- Rabbit
- Mouse
- Goat
- Others
Applications
- Laboratory
- Hospital
- Others
Companies covered
- Abcam
- Abnova
- Absolute Antibody
- Agrisera
- BioLegend
- Bio-Rad
- Bon Opus Biosciences
- Boster
- Creative Biomart
- Enzo Life Sciences
- ImmunoStar
- LifeSpan Biosciences
- MilliporeSigma
- Novus Biologicals
- OriGene
- ProMab
- R&D Systems
- Rockland Immunochemicals
- Santa Cruz Biotechnology
- Sino Biological
- US Biological
- Thermo Fisher
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Human VEGF Antibody Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Human VEGF Antibody Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Human VEGF Antibody Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Human VEGF Antibody Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Human VEGF Antibody Market Dynamics
- 2.1 Human VEGF Antibody Industry Trends
- 2.2 Human VEGF Antibody Industry Drivers
- 2.3 Human VEGF Antibody Industry Opportunities and Challenges
- 2.4 Human VEGF Antibody Industry Restraints
3 Human VEGF Antibody Market by Manufacturers
- 3.1 Global Human VEGF Antibody Revenue by Manufacturers (2021-2026)
- 3.2 Global Human VEGF Antibody Sales by Manufacturers (2021-2026)
- 3.3 Global Human VEGF Antibody Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Human VEGF Antibody Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Human VEGF Antibody Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Human VEGF Antibody Manufacturers, Product Type & Application
- 3.7 Global Human VEGF Antibody Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Human VEGF Antibody Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Human VEGF Antibody Players Market Share by Revenue in 2025
- 3.8.3 2025 Human VEGF Antibody Tier 1, Tier 2, and Tier 3
4 Human VEGF Antibody Market by Type
- 4.1 Human VEGF Antibody Type Introduction
- 4.1.1 Rabbit
- 4.1.2 Mouse
- 4.1.3 Goat
- 4.1.4 Others
- 4.2 Global Human VEGF Antibody Sales by Type
- 4.2.1 Global Human VEGF Antibody Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Human VEGF Antibody Sales by Type (2021-2032)
- 4.2.3 Global Human VEGF Antibody Sales Market Share by Type (2021-2032)
- 4.3 Global Human VEGF Antibody Revenue by Type
- 4.3.1 Global Human VEGF Antibody Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Human VEGF Antibody Revenue by Type (2021-2032)
- 4.3.3 Global Human VEGF Antibody Revenue Market Share by Type (2021-2032)
5 Human VEGF Antibody Market by Application
- 5.1 Human VEGF Antibody Application Introduction
- 5.1.1 Laboratory
- 5.1.2 Hospital
- 5.1.3 Others
- 5.2 Global Human VEGF Antibody Sales by Application
- 5.2.1 Global Human VEGF Antibody Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Human VEGF Antibody Sales by Application (2021-2032)
- 5.2.3 Global Human VEGF Antibody Sales Market Share by Application (2021-2032)
- 5.3 Global Human VEGF Antibody Revenue by Application
- 5.3.1 Global Human VEGF Antibody Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Human VEGF Antibody Revenue by Application (2021-2032)
- 5.3.3 Global Human VEGF Antibody Revenue Market Share by Application (2021-2032)
6 Global Human VEGF Antibody Sales by Region
- 6.1 Global Human VEGF Antibody Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Human VEGF Antibody Sales by Region (2021-2032)
- 6.2.1 Global Human VEGF Antibody Sales by Region (2021-2026)
- 6.2.2 Global Human VEGF Antibody Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Human VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Human VEGF Antibody Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Human VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Human VEGF Antibody Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Human VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Human VEGF Antibody Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Human VEGF Antibody Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Human VEGF Antibody Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Human VEGF Antibody Revenue by Region
- 7.1 Global Human VEGF Antibody Revenue by Region
- 7.1.1 Global Human VEGF Antibody Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Human VEGF Antibody Revenue by Region (2021-2026)
- 7.1.3 Global Human VEGF Antibody Revenue by Region (2027-2032)
- 7.1.4 Global Human VEGF Antibody Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Human VEGF Antibody Revenue (2021-2032)
- 7.2.2 North America Human VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Human VEGF Antibody Revenue (2021-2032)
- 7.3.2 Europe Human VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Human VEGF Antibody Revenue (2021-2032)
- 7.4.2 Asia-Pacific Human VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Human VEGF Antibody Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Human VEGF Antibody Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Abcam
- 8.1.1 Abcam Company Information
- 8.1.2 Abcam Business Overview
- 8.1.3 Abcam Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Abcam Human VEGF Antibody Product Portfolio
- 8.1.5 Abcam Recent Developments
- 8.2 Abnova
- 8.2.1 Abnova Company Information
- 8.2.2 Abnova Business Overview
- 8.2.3 Abnova Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Abnova Human VEGF Antibody Product Portfolio
- 8.2.5 Abnova Recent Developments
- 8.3 Absolute Antibody
- 8.3.1 Absolute Antibody Company Information
- 8.3.2 Absolute Antibody Business Overview
- 8.3.3 Absolute Antibody Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Absolute Antibody Human VEGF Antibody Product Portfolio
- 8.3.5 Absolute Antibody Recent Developments
- 8.4 Agrisera
- 8.4.1 Agrisera Company Information
- 8.4.2 Agrisera Business Overview
- 8.4.3 Agrisera Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Agrisera Human VEGF Antibody Product Portfolio
- 8.4.5 Agrisera Recent Developments
- 8.5 BioLegend
- 8.5.1 BioLegend Company Information
- 8.5.2 BioLegend Business Overview
- 8.5.3 BioLegend Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 BioLegend Human VEGF Antibody Product Portfolio
- 8.5.5 BioLegend Recent Developments
- 8.6 Bio-Rad
- 8.6.1 Bio-Rad Company Information
- 8.6.2 Bio-Rad Business Overview
- 8.6.3 Bio-Rad Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Bio-Rad Human VEGF Antibody Product Portfolio
- 8.6.5 Bio-Rad Recent Developments
- 8.7 Bon Opus Biosciences
- 8.7.1 Bon Opus Biosciences Company Information
- 8.7.2 Bon Opus Biosciences Business Overview
- 8.7.3 Bon Opus Biosciences Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Bon Opus Biosciences Human VEGF Antibody Product Portfolio
- 8.7.5 Bon Opus Biosciences Recent Developments
- 8.8 Boster
- 8.8.1 Boster Company Information
- 8.8.2 Boster Business Overview
- 8.8.3 Boster Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Boster Human VEGF Antibody Product Portfolio
- 8.8.5 Boster Recent Developments
- 8.9 Creative Biomart
- 8.9.1 Creative Biomart Company Information
- 8.9.2 Creative Biomart Business Overview
- 8.9.3 Creative Biomart Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Creative Biomart Human VEGF Antibody Product Portfolio
- 8.9.5 Creative Biomart Recent Developments
- 8.10 Enzo Life Sciences
- 8.10.1 Enzo Life Sciences Company Information
- 8.10.2 Enzo Life Sciences Business Overview
- 8.10.3 Enzo Life Sciences Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Enzo Life Sciences Human VEGF Antibody Product Portfolio
- 8.10.5 Enzo Life Sciences Recent Developments
- 8.11 ImmunoStar
- 8.11.1 ImmunoStar Company Information
- 8.11.2 ImmunoStar Business Overview
- 8.11.3 ImmunoStar Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 ImmunoStar Human VEGF Antibody Product Portfolio
- 8.11.5 ImmunoStar Recent Developments
- 8.12 LifeSpan Biosciences
- 8.12.1 LifeSpan Biosciences Company Information
- 8.12.2 LifeSpan Biosciences Business Overview
- 8.12.3 LifeSpan Biosciences Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 LifeSpan Biosciences Human VEGF Antibody Product Portfolio
- 8.12.5 LifeSpan Biosciences Recent Developments
- 8.13 MilliporeSigma
- 8.13.1 MilliporeSigma Company Information
- 8.13.2 MilliporeSigma Business Overview
- 8.13.3 MilliporeSigma Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 MilliporeSigma Human VEGF Antibody Product Portfolio
- 8.13.5 MilliporeSigma Recent Developments
- 8.14 Novus Biologicals
- 8.14.1 Novus Biologicals Company Information
- 8.14.2 Novus Biologicals Business Overview
- 8.14.3 Novus Biologicals Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Novus Biologicals Human VEGF Antibody Product Portfolio
- 8.14.5 Novus Biologicals Recent Developments
- 8.15 OriGene
- 8.15.1 OriGene Company Information
- 8.15.2 OriGene Business Overview
- 8.15.3 OriGene Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.15.4 OriGene Human VEGF Antibody Product Portfolio
- 8.15.5 OriGene Recent Developments
- 8.16 ProMab
- 8.16.1 ProMab Company Information
- 8.16.2 ProMab Business Overview
- 8.16.3 ProMab Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.16.4 ProMab Human VEGF Antibody Product Portfolio
- 8.16.5 ProMab Recent Developments
- 8.17 R&D Systems
- 8.17.1 R&D Systems Company Information
- 8.17.2 R&D Systems Business Overview
- 8.17.3 R&D Systems Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.17.4 R&D Systems Human VEGF Antibody Product Portfolio
- 8.17.5 R&D Systems Recent Developments
- 8.18 Rockland Immunochemicals
- 8.18.1 Rockland Immunochemicals Company Information
- 8.18.2 Rockland Immunochemicals Business Overview
- 8.18.3 Rockland Immunochemicals Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.18.4 Rockland Immunochemicals Human VEGF Antibody Product Portfolio
- 8.18.5 Rockland Immunochemicals Recent Developments
- 8.19 Santa Cruz Biotechnology
- 8.19.1 Santa Cruz Biotechnology Company Information
- 8.19.2 Santa Cruz Biotechnology Business Overview
- 8.19.3 Santa Cruz Biotechnology Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.19.4 Santa Cruz Biotechnology Human VEGF Antibody Product Portfolio
- 8.19.5 Santa Cruz Biotechnology Recent Developments
- 8.20 Sino Biological
- 8.20.1 Sino Biological Company Information
- 8.20.2 Sino Biological Business Overview
- 8.20.3 Sino Biological Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.20.4 Sino Biological Human VEGF Antibody Product Portfolio
- 8.20.5 Sino Biological Recent Developments
- 8.21 US Biological
- 8.21.1 US Biological Company Information
- 8.21.2 US Biological Business Overview
- 8.21.3 US Biological Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.21.4 US Biological Human VEGF Antibody Product Portfolio
- 8.21.5 US Biological Recent Developments
- 8.22 Thermo Fisher
- 8.22.1 Thermo Fisher Company Information
- 8.22.2 Thermo Fisher Business Overview
- 8.22.3 Thermo Fisher Human VEGF Antibody Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.22.4 Thermo Fisher Human VEGF Antibody Product Portfolio
- 8.22.5 Thermo Fisher Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Human VEGF Antibody Value Chain Analysis
- 9.1.1 Human VEGF Antibody Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Human VEGF Antibody Production Mode & Process
- 9.2 Human VEGF Antibody Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Human VEGF Antibody Distributors
- 9.2.3 Human VEGF Antibody Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$3,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst